

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ASCENTAGE PHARMA GROUP INTERNATIONAL**

**亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### **UPDATE ANNOUNCEMENT**

#### **GRANT OF AWARDS UNDER THE 2021 RSU SCHEME**

Reference is made to the announcements of Ascentage Pharma Group International (the “**Company**”, together with its subsidiaries, the “**Group**”) dated February 2, 2021 (the “**Adoption Announcement**”), May 21, 2021 (the “**Grant Announcement**”) and May 26, 2021 (collectively, the “**Announcements**”) in relation to, among other things, the proposed grant of RSUs under the 2021 RSU Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Adoption Announcement and the Grant Announcement.

#### **GRANT OF AWARDS UNDER THE 2021 RSU SCHEME**

As disclosed in the Grant Announcement, on May 17, 2021, the Company granted an aggregate of 385,333 RSUs under the 2021 RSU Scheme, representing 385,333 Shares to a total of 33 Independent Selected Persons, who are employees of the Group.

Due to the termination of the employment of one of the Independent Selected Persons who was originally expected to be granted 10,641 RSUs under the 2021 RSU Scheme, the Company would like to update the shareholders of the Company that the grant of awards to the Independent Selected Persons as disclosed in the Grant Announcement shall be adjusted accordingly, pursuant to which the Company will now grant an aggregate of 374,692 RSUs under the 2021 RSU Scheme, representing 374,692 Shares to a total of 32 Independent Selected Persons, who are employees of the Group.

The underlying Shares of the RSUs granted to the Independent Selected Persons as abovementioned represent approximately 0.15% of the total issued share capital of the Company as at the date of this announcement, and approximately 0.15% of the enlarged total issued share capital of the Company (assuming there will be no change in the total issued share capital from the date of this announcement up to the exercise of the RSUs granted to the Independent Selected Persons other than the allotment and issuance of such underlying Shares by the Company to the Trustee).

## **GENERAL**

The RSU Scheme does not involve the grant of options in respect of new shares or other new securities of the Company or any of its subsidiaries, and is therefore not within the scope of, and subject to, Chapter 17 of the Listing Rules.

Save as disclosed above, all other information as set out in the Announcements remain unchanged and shall continue to be valid for all purposes. This announcement is an update to and should be read in conjunction with the Announcements.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, June 18, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*